Evaluation of NTP42, a novel thromboxane receptor antagonist, in a first-in-human phase I clinical trial

• Main Authors: Helen M. Reid (Author), Mark Maginn (Author), C. Michael Perkins (Author), Eamon P. Mulvaney (Author), Malcolm Boyce (Author), Takahiro Yamamoto (Author), B. Therese Kinsella (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: The thromboxane receptor (TP) antagonist NTP42 is in clinical development for treatment of cardiopulmonary diseases, such as pulmonary arterial hypertension. In this randomized, placebo-controlled Phase I clinical trial, NTP42, administered as the oral formulation NTP42:KVA4, was evaluat...